Insider filing
Traded Oct 10 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Oct 12, 2026 · Notice filed Oct 12, 2026
A Zevra Therapeutics officer told the SEC about a plan to sell $228K of Zevra Therapeutics shares around Oct 12, 2026. The filing says the shares were acquired as compensation. That is a tiny part of all Zevra Therapeutics shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider filing
Traded Oct 10 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Neil F. Mcfarlane (President and CEO) sold ~$225K of Zevra Therapeutics
Planned saleInsider filing
Traded Oct 10 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.